CROI 2017 Program and Information

Program and Agenda

Poster Sessions • Tuesday Isabelle Malet 1 , Frédéric Subra 2 , Charlotte Charpentier 3 , Gilles Collin 4 , Diane Descamps 4 , Vincent Calvez 1 , Anne-Geneviève Marcelin 1 , Olivier Delelis 2 1 Pitie-Salpetriere Hosp, Paris, France, 2 Ecole Normale Supérieure de Cachan, Cachan, France, 3 INSERM, Paris, France, 4 Bichat Hosp, Paris, France 500LB EMERGENCE OF INTEGRASE RESISTANCEMUTATIONS DURING INITIAL THERAPYWITH TDF/FTC/DTG 496 IMPACT OF CLINICALLY OBSERVED INTEGRASEMUTATIONS ON DOLUTEGRAVIR RESISTANCE Atsuko Hachiya , Masaaki Nakashima, Yoko Ido, Urara Shigemi, Masakazu Matsuda, Reiko Okazaki, Junji Imamura, Yoshiyuki Yokomaku, Yasumasa Iwatani Natl Hosp Org Nagoya Med Cntr, Nagoya, Japan 497 BICTEGRAVIR DISSOCIATIONHALF-LIFE FROMHIV-1 G140S+Q148H INTEGRASE/DNA COMPLEXES Kirsten L. White , Anita Niedziela-Majka, Nikolai Novikov, Michael D. Miller, Haolun Jin, Scott E. Lazerwith, Manuel Tsiang Gilead Scis, Inc, Foster City, CA, USA 498 PHENOTYPIC SUSCEPTIBILITY OF SIV AND HIV-1VARIANTS TO BICTEGRAVIR, A NOVEL INSTI Said Hassounah , Thibault Mesplede, Bonnie Spira, Nathan Osman, Mark A. Wainberg McGill Univ, Montréal, Quebec, Canada 499 A HIGH-LEVEL RESISTANCE TO INTEGRASE INHIBITORS SELECTED OUTSIDE INTEGRASE HIV-1 GENE Poster P-J4 REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE Poster Hall - 4 EF 2:30 PM - 4:00 PM 501 CROSS-RESISTANCE PROFILES OF THE NNRTIS IN DEVELOPMENT TO PREVENT HIV-1 INFECTION Nicholas S. Giacobbi , Nicolas Sluis-Cremer Univ of Pittsburgh, Pittsburgh, PA, USA 502 DRUG RESISTANCE AFTER CESSATION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT Gbolahan Ajibola 1 , Christopher Rowley 2 , Kathleen M. Powis 3 , Sikhulile Moyo 1 , Jean Leidner 4 , Kara Bennett 5 , Florence Chilisa 1 , Joseph Makhema 1 , Roger L. Shapiro 2 , Shahin Lockman 2 1 Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 2 Harvard Univ, Boston, MA, USA, 3 Massachusetts General Hosp, Boston, MA, USA, 4 Goodtables Consulting, Oklahoma, OK, USA, 5 Bennett Statistical Consulting Inc, New York, NY, USA 503 4'-MODIFIED NRTIS’POTENT ANTI-HIV ACTIVITY STEMS FROM STRONG RT ACTIVE-SITE BINDING Jennifer A. Fulcher 1 , Yushen Du 1 , Ren Sun 1 , Raphael J. Landovitz 2 1 Univ of California Los Angeles, Los Angeles, CA, USA, 2 UCLA Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA

Kenji Maeda 1 , Yuki Takamatsu 2 , Debananda Das 2 , Satoru Kohgo 3 , Shinichiro Hattori 1 , Hironori Hayashi 1 , Kouki Matsuda 1 , Stefan G. Sarafianos 4 , Hiroaki Mitsuya 2 1 Natl Cntr for Global Hlth and Med Rsr Inst, Shinjuku, Tokyo, Japan 2 NIH, Bethesda, MD, USA, 3 Sojo Univ, Kumamoto, Japan, 4 Univ of Missouri, Columbia, MO, USA

CROI 2017 90